For Andrew Hanna, adapting to changing situations on stage teaches him how to adapt to the many challenges in life. The ...

Layla-Grace is a happy, determined and chatty little girl who loves music and playing outside. The 18-month-old has been diagnosed with Achondroplasia – a rare bone disorder that results in dwarfism.

Mizuho Securities analyst Salim Syed assigned a Buy rating on BridgeBio Pharma (BBIO – Research Report) on June 4 and set a price target ...

BridgeBio Pharma, Inc. (NASDAQ: BBIO) has announced positive and sustained results from its Phase 2 trial of the investigational therapy infigratinib in children with achondroplasia. The trial, known ...

Overview A type of bone growth disorder. Due to genetic mutations, the cartilage does not convert into a bone during fetal ...

Bridgebio Pharma Inc.’s data from the phase II study with infigratinib in achondroplasia “swings the pendulum of debate ...

BridgeBio Pharma revealed results from the PROPEL 2 Phase 2 trial of infigratinib in children with achondroplasia. Key data ...

BBIO Price Action: At the time of writing, BridgeBio shares are trading 4.5% lower at $27.65, according to data from Benzinga Pro.

BridgeBio stock rose early Tuesday after the drugmaker's growth disorder treatment topped Wall Street's expectations in a Phase 2 study.Please watch the video at Investors.com - Glitches, Elections ...

Longer follow-up results from a mid-stage trial indicate the company’s treatment for a genetic cause of dwarfism may be competitive to an approved therapy from BioMarin Pharmaceutical.

BridgeBio Pharma has bounced back from the withdrawal of infigratinib in oncology, linking the molecule to a BioMarin-beating ...

BridgeBio touted longer-term data for its achondroplasia drug infigratinib from a mid-stage trial on Tuesday, setting the ...